



CD30 (CON6D/B5): sc-59015

BACKGROUND

The tumor necrosis factor (TNF) receptor family is composed of several type I integral membrane glycoproteins that exhibit homology in their cysteine-rich extracellular domains. Members of this family include FAS, OX40, CD27 and CD30. Ligands for these receptors are often type II transmembrane glycoproteins, as is the case for CD27 and CD30. CD27 is a 55 kDa homodimeric lymphocyte-specific surface antigen present on T and B lymphocytes. Activation of the CD3 complex via the T cell receptor for antigen leads to an increase in CD27 expression. Together, CD27 and its ligand, CD27L, generate co-stimulatory signals required for complete T cell activation. CD30 is a 120 kDa surface marker for neoplastic cells of the Hodgkin's lymphoma and related hematologic malignancies. CD30L has been shown to enhance the proliferation of the Hodgkin's cell line HDLM-2, but exerts antiproliferative effects on large cell anaplastic lymphoma cell lines.

REFERENCES

- Smith, C.A., Gruss, H.J., Davis, T., Anderson, D., Farrah, T., Baker, E., Sutherland, G.R., Brannan, C.I., Copeland, N.G., Jenkins, N.A., Grabstein, K.H., Gliniak, B., McAlister, I.B., Fanslow, W., Alderson, M., Falk, B., Gimpel, S., Gillis, S., Din, W.S., Goodwin, R.G. and Armitage, R.J. 1993. CD30 antigen, a marker for Hodgkin's lymphoma, is a receptor whose ligand defines an emerging family of cytokines with homology to TNF. *Cell* 73: 1349-1360.
- Armitage, R.J. 1994. Tumor necrosis factor receptor superfamily members and their ligands. *Curr. Opin. Immunol.* 6: 407-413.
- Hintzen, R.Q., de Jong, R., Lens, S.M. and van Lier, R.A. 1994. CD27: marker and mediator of T cell activation. *Immunol. Today* 15: 307-311.
- Gruss, H.J. and Dower, S.K. 1995. Tumor necrosis factor ligand superfamily: involvement in the pathology of malignant lymphomas. *Blood* 85: 3378-3404.
- Lens, S.M., de Jong, R., Hintzen, R.Q., Koopman, G., van Lier, R.A. and van Oers, R.H. 1995. CD27-CD70 interaction: unravelling its implication in normal and neoplastic B cell growth. *Leuk. Lymph.* 18: 51-59.
- Wendtner, C.M., Schmitt, B., Gruss, H.J., Druker, B.J., Emmerich, B., Goodwin, R.G. and Hallek, M. 1995. CD30 ligand signal transduction involves activation of a tyrosine kinase and of mitogen-activated protein kinase in a Hodgkin's lymphoma cell line. *Cancer Res.* 55: 4157-4161.
- Bowen, M.A., Lee, R.K., Miragliotta, G., Nam, S.Y. and Podack, E.R. 1996. Structure and expression of murine CD30 and its role in cytokine production. *J. Immunol.* 156: 442-449.

CHROMOSOMAL LOCATION

Genetic locus: TNFRSF8 (human) mapping to 1p36; Tnfrsf8 (mouse) mapping to 4 E1.

SOURCE

CD30 (CON6D/B5) is a mouse monoclonal antibody raised against L428 Hodgkin's lymphoma cell line of human origin.

PRODUCT

Each vial contains 200 µg IgG_{2a} in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin.

APPLICATIONS

CD30 (CON6D/B5) is recommended for detection of CD30 of human origin by immunofluorescence and immunohistochemistry (including paraffin-embedded sections) (starting dilution 1:50, dilution range 1:50-1:500) and flow cytometry (1 µg per 1 x 10⁶ cells).

Suitable for use as control antibody for CD30 siRNA (h): sc-29991.

Molecular Weight of CD30: 120 kDa.

RECOMMENDED SECONDARY REAGENTS

To ensure optimal results, the following support (secondary) reagents are recommended: 1) Immunofluorescence: use goat anti-mouse IgG-FITC: sc-2010 (dilution range: 1:100-1:400) or goat anti-mouse IgG-TR: sc-2781 (dilution range: 1:100-1:400) with UltraCruz™ Mounting Medium: sc-24941. 2) Immunohistochemistry: use ImmunoCruz™: sc-2050 or ABC: sc-2017 mouse IgG Staining Systems.

STORAGE

Store at 4° C, ****DO NOT FREEZE****. Stable for one year from the date of shipment. Non-hazardous. No MSDS required.

RESEARCH USE

For research use only, not for use in diagnostic procedures.

PROTOCOLS

See our web site at www.scbt.com or our catalog for detailed protocols and support products.